Borrui Pharmaceuticals’ application for clinical trial of BGM0504 tablets in overweight/obese adults has been approved.
September 17, 2025
Source: drugdu
122
Borrui Pharmaceuticals(688166) announced on the evening of September 15th that its wholly-owned subsidiary, Borrui Pharmaceutical, recently received a "Notice of Approval for Drug Clinical Trial" from the National Medical Products Administration (NMPA), authorizing the clinical trial of Borrui Pharmaceutical's BGM0504 tablets in overweight/obese adults. BGM0504 is a dual agonist of the GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide) receptors independently developed by the company. It activates the downstream pathways of GIP and GLP-1, resulting in biological effects such as blood sugar control, weight loss, and the treatment of non-alcoholic steatohepatitis (NASH), demonstrating potential for the treatment of various metabolic diseases. BGM0504 injection is currently in Phase III clinical trials in China for both type 2 diabetes and weight loss. BGM0504 tablets are the oral formulation of BGM0504. As of the date of this announcement, no oral formulations targeting this target have been approved for marketing globally.
https://finance.eastmoney.com/a/202509153513828386.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
